During the second day of the ongoing Middle East Obstetric and Gynecology Congress in Dubai, Genpharm sponsored a CME conference on the Non-Invasive Prenatal Diagnostic Prenatest™.

The Conference was chaired by Professor Dr. Ahmed Badreldeen, Obstetrics and Feto-Maternal Medicine Specialist practicing in Doha, Qatar.  The presentation was delivered by  PD Dr. rer. nat. Markus Stumm, Biologist, Partner and Manager, BG Berlin-Genetics GmbH, who said: “It is extremely important to offer this vital information to physicians in the region. The free to attend presentation on non-invasive prenatal detection attracted great interest from the audience followed by an interactive questioning session.”

Due to the high interest, Dr Stumm was asked to deliver a repeat lecture earlier this afternoon. “We are extremely happy to see the physicians responsiveness to this new technology. They appreciate the science behind this innovative Pre-natal diagnostic test of fetal trisomies 18, 13 and 21. Genpharm is very proud to be the pioneer in bringing this breakthrough innovation to the MENA region. Pregnant mothers have now an alternative to the classical invasive techniques that carry several risks. Prenatest™ is safe to both mothers and fetuses. It is currently the first and only European approved, CE marked NIPT diagnostic tool. Its effectiveness in term of accuracy and specificity is supported by a robust clinical data set”, said Karim Smaira, CEO of Genpharm.